Related Experiment Video
Updated: Jan 26, 2026

Culture of Bladder Cancer Organoids as Precision Medicine Tools
Published on: December 28, 2021
Targeted therapies in urothelial bladder cancer: a disappointing past preceding a bright future?
Joya-Rita Hindy1, Tarek Souaid1, Hampig Raphael Kourie1,2
1Medical Genetics Unit, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.
Abstract:
Bladder cancer (BC) is the most frequent cancer affecting the urinary tract. With the growing era of targeted therapies around the 2000s, many trials evaluated the efficacy of targeted therapy in advanced BC. However, no approval was given yet to any form of targeted therapy when it comes to BC. The aim of this paper was to report the most pivotal trials that evaluated different families of targeted therapy in the treatment of BC, according to their biomarkers (FGFR3, EGFR, HER2, VEGF and PI3K/AKT/mTOR). The ongoing trials testing targeted therapies in advanced BC were then summarized. Finally, the different immunotherapies approved for this disease and their potential combination with targeted therapy were addressed.
Insights
Targeted therapies show promise for advanced bladder cancer (BC) but lack approval. This review covers pivotal trials, ongoing studies, and immunotherapy combinations for BC treatment.
Area of Science:
- Uro-oncology
- Cancer Therapeutics
- Clinical Trials
Background:
- Bladder cancer (BC) is a prevalent urinary tract malignancy.
- Targeted therapies have been investigated for advanced BC since the 2000s.
- Despite extensive research, no targeted therapy is currently approved for BC.
Purpose of the Study:
- To review pivotal clinical trials of targeted therapies in advanced bladder cancer.
- To summarize ongoing trials evaluating targeted therapies based on specific biomarkers.
- To discuss approved immunotherapies and their potential combination with targeted agents for BC.
Main Methods:
- Literature review of clinical trials in advanced bladder cancer.
- Analysis of targeted therapy efficacy based on biomarkers: FGFR3, EGFR, HER2, VEGF, and PI3K/AKT/mTOR.
- Summary of ongoing clinical trials and approved immunotherapies.
Main Results:
- Numerous trials have evaluated targeted therapies in advanced BC with varying biomarker targets.
- No targeted therapy has yet received regulatory approval for bladder cancer treatment.
- Several immunotherapies are approved, with ongoing research into combinations with targeted agents.
Conclusions:
- Targeted therapy development for bladder cancer has faced challenges, with no approvals to date.
- Ongoing trials and the exploration of immunotherapy combinations offer future therapeutic avenues.
- Biomarker-driven approaches remain critical for advancing bladder cancer treatment strategies.
More Related Videos
09:28Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis
Published on: May 12, 2019
07:33Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
Published on: September 19, 2025
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Urinary Bladder
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
Gene Therapy
Anatomy of the Genitourinary System II: Bladder and Urethra
Group Therapy